Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Burger, Jan A., Sivina, Mariela, Jain, Nitin, Kim, Ekaterina, Kadia, Tapan, Estrov, Zeev, Nogueras-Gonzalez, Graciela M., Huang, Xuelin, Jorgensen, Jeffrey, Li, Jianling, Cheng, Mei, Clow, Fong, Ohanian, Maro, Andreeff, Michael, Mathew, Thomas, Thompson, Philip, Kantarjian, Hagop, O’Brien, Susan, Wierda, William G., Ferrajoli, Alessandra, Keating, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6405333/
https://ncbi.nlm.nih.gov/pubmed/30530801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-10-879429
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados